By Dean Seal
Shares of NeurAxis more than doubled after regulators cleared its IB-Stim treatment for pediatric functional abdominal pain related to functional dyspepsia.
The stock briefly touched a record high of $6.20 before settling back around $4.97 in early trading. Shares closed the market at $5.27 this time a year ago.
The medical technology company said before the opening bell that the U.S. Food and Drug Administration's 510(k) clearance for IB-Stim in patients aged 8 to 21 marks the first time that the FDA has approved a treatment related to functional dyspepsia.
This is also the second successful expansion of the FDA's indication for IB-Stim after previously getting it approved for abdominal pain associated with irritable bowel syndrome, NeurAxis said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 20, 2025 10:20 ET (14:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.